Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Tiziana Life Sciences ( (TLSA) ) has issued an update.
On September 5, 2025, Tiziana Life Sciences announced that its Executive Chairman and Founder, Mr. Gabriele Cerrone, purchased 25,000 common shares at $1.60 each, increasing his total holdings to 43,277,143 shares, representing 36.28% of the company’s issued share capital. This purchase underscores the chairman’s confidence in the company’s strategic direction and its lead candidate, foralumab, which is undergoing trials for non-active secondary progressive multiple sclerosis. The company’s focus on intranasal delivery of foralumab represents a novel approach in the treatment of neuroinflammatory diseases, potentially enhancing efficacy and safety compared to traditional methods.
The most recent analyst rating on (TLSA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Tiziana Life Sciences stock, see the TLSA Stock Forecast page.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company’s lead development candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which is currently in clinical trials for treating neuroinflammatory and neurodegenerative diseases.
Average Trading Volume: 341,487
Technical Sentiment Signal: Buy
Current Market Cap: $176.1M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.